RVMD ▼ -2.4% - Revolution Medicines, Inc. $RVMD - European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer 16-NOV-2026 01:00 PM ET